Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Focal Segmental Glomerulosclerosis – Pipeline Review, H2 2016, provides an overview of the Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline landscape.
Focal Segmental glomerulosclerosis is a rare disease that attacks the kidney’s filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Symptoms include proteinuria, edema, high cholesterol, high blood pressure and poor appetite. Risk factors include infection, obesity, sickle cell disease and reflux nephropathy. Treatment includes antibiotics, vitamin D supplements, and immunosuppressive drugs.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Focal Segmental Glomerulosclerosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Soluble Guanylate Cyclase - Pipeline Review, H2 2020
Summary
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble...
Cervical Cancer Diagnostics and Therapeutics Market Report Overview Cervical Cancer Diagnostics and Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Cervical Cancer Diagnostics and Therapeutics market types and applications....
Dermatological Therapeutics Market Report Overview Dermatological Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Dermatological Therapeutics market types and applications. It is a focused study on Dermatological Therapeutics...
Gastrointestinal Therapeutics Market Report Overview Gastrointestinal Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Gastrointestinal Therapeutics market types and applications. It is a focused study on Gastrointestinal...
Liver Cancer Therapeutics Market Report Overview Liver Cancer Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Liver Cancer Therapeutics market types and applications. It is a focused study on Liver Cancer Therapeutics market...
Melanoma Diagnostics and Therapeutics Market Report Overview Melanoma Diagnostics and Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Melanoma Diagnostics and Therapeutics market types and applications. It is a focused...
Peptide Therapeutics Market Report Overview Peptide Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Peptide Therapeutics market types and applications. It is a focused study on Peptide Therapeutics market space including...
189 pages •
By Global Industry Analysts
• Mar 2021
Project Details:
- StrategyR - A Trademark of Global Industry Analysts, Inc.
- Project Edition: 8
- Influencer Pool: 1252
- MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies....
The global energy-based therapeutics market reached a value of US$ 6.14 Billion in 2020. Energy-based therapeutics are employed for the modification or destruction of tissues with the help of technologies such as microwave, thermal, hydro-mechanical, radiofrequency, cryotherapy, and ultrasound. These therapeutics are divided on the basis of...
Therapy
World
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.